{
    "nctId": "NCT00437359",
    "briefTitle": "Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer",
    "officialTitle": "Antiestrogen vs Aromatase Inhibitor After Chemotherapy for Adjuvant Setting: Efficacy of Endocrine Therapy After Chemotherapy in Postoperative Adjuvant Therapy for Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 240,
    "primaryOutcomeMeasure": "Recurrence-free rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Written consent obtained for study participation.\n* Breast cancer diagnosed histologically with a breast removed or preserved.\n* Positive ER or PR testing by immunohistochemistry (IHC), enzyme immunoassay (EIA) and who meet the criteria of each institution.\n* HER2 evaluation.\n* Patient Status (PS): 0 or 1.\n* Fully functional heart, liver, kidneys, and bone marrow.\n* More than one year since last menstruation or tested postmenopausal from estradiol (E2) and follicle-stimulating hormone (FSH) levels based on evaluation standard of each institution.\n* Expected to live for at least three months (or longer) after study commencement.\n\nExclusion Criteria:\n\n* Pregnant or breast feeding.\n* Bilateral or inflammatory breast cancer.\n* Multiple cancers.\n* Life-threatening metastases.\n* History of serious hypersensitivity.\n* Judged ineligible for the study by the study doctor.",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}